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Introduction
Osteoarthritis is the most common form of arthritis worldwide, aff ecting about 40% of people older than 70 years. 1 It is a complex disease of the musculoskeletal system with both genetic and environmental risk factors. 2 From the results of heritability studies in twins, sibling pairs, and families, genetic factors are estimated to account for about 50% of the risk of developing osteoarthritis in the hip or knee, although precise estimates vary according to sex, aff ected site, and severity of disease. 3, 4 Despite extensive eff orts, only three loci (GDF5, chromosome 7q22, and MCF2L) [5] [6] [7] [8] [9] [10] [11] have thus far been associated with osteoarthritis at genome-wide signifi cance levels (p≤5·0×10 -⁸) in European populations. This lack of success in osteoarthritis might be attributed to several factors such as insuffi cient sample sizes in previous studies and disease hetero geneity that might result from diff erent underlying causes, both genetic and environmental, depending on which joints are aff ected. 4 The three established osteoarthritis loci have fairly small eff ect sizes (allele-wise odds ratios [OR] of about 1·15) and we have previously shown that the genetic basis of osteoarthritis is likely to consist of several signals of similar or smaller magnitude that necessitate large sample sizes for their detection at genome-wide signifi cance levels. 12 Pheno type defi nition in cases and controls is also a likely factor contributing to the dilution of power to detect strong signals. Improved defi nition of phenotype and reduced misclassifi cation in such a prevalent disorder can enhance power.
To identify additional loci that confer susceptibility to osteoarthritis, we undertook a large well powered genome-wide association study (GWAS) of osteoarthritis within the context of the Arthritis Research UK Osteoarthritis Genetics (arcOGEN) Consortium. In 2011, we reported the results of an interim analysis of 43·8% of the full GWAS sample size, detecting no novel loci for osteoarthritis, but showing the polygenic nature of the disease's underlying genetics. 12 Here, we report the results of the full-scale arcOGEN GWAS.
Methods

Study population
We undertook a large case-control genome-wide association study (GWAS) in which 7410 unrelated patients were retrospectively and prospectively selected from hospitals and clinics, with about 80% of patients ascertained for the severe endpoint of total joint 
Procedures
The arcOGEN samples were genotyped by use of Illumina Human 610-Quad BeadChips (Illumina, San Diego, CA, USA; appendix p 2). Most cases had primary osteoarthritis requiring joint replacement of the hip or knee (table 1) . We did quality-control checks both at the sample and single nucleotide polymorphism (SNP) levels (appendix p 2). We did a case-control analysis for an overlapping set of 485 491 autosomal SNPs in 7410 arcOGEN cases of osteoarthritis and 11 009 controls (table 1; appendix p 2, p 73). We imputed genotypes for autosomal SNPs by use of the directly typed data and phased genotype data from all HapMap III populations but did not see any additional signals (p<10 -⁵) arising from imputed SNPs that were not captured by the directly genotyped SNP analyses (appendix p 3, p 6). To assess the eff ect of phenotype misclassifi cation in controls, we also analysed genomewide genotypes in 4476 female cases of osteoarthritis from arcOGEN compared with 1828 osteoarthritis-free female controls from the TwinsUK dataset. We used a multiplicative model for the analysis of all data and also stratifi ed by site of osteoarthritis, sex, and osteoarthritis severity-ie, only cases with TJR were assessed (for a total of 24 specifi c phenotypes). We have presented the results for all analyses in the appendix pp 81-98, and for the most signifi cant specifi c phenotype in the main text. 129 prioritised SNPs (p<10 -⁵) were followed up by in-silico replication in the studies deCODE, EGCUT, GARP, Rotterdam study RSI and RSII cohorts, and TwinsUK (total in-silico replication sample size of 5064 cases of osteoarthritis and 40 619 controls). We subsequently undertook a de-novo replication of the 26 most signifi cant SNPs in an additional independent set of 2409 arcOGEN cases of osteoarthritis and 2319 WTCCC2 populationbased controls (UK repli cation). For our primary analysis, we used a meta-analysis framework to combine results for all data (discovery and replication) by use of a fi xedeff ects model (appendix p 5).
We used RT-PCR to assess the expression of at least one gene per signal in joint tissues from patients with osteoarthritis who were undergoing TJR, and in cartilage from individuals without clinical osteoarthritis. We investigated the expression patterns of nucleostemin, encoded by the GNL3 gene, through immunohistochemical staining of normal and osteoarthritic 
Statistical analysis
Statistical and imputational methods and HardyWeinberg equilibrium are described in the appendix pp 2-5.
Role of the funding source
The sponsors of the study had no role in the study design, data collection, analysis or interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Genome-wide analysis showed an excess of signals compared with the null expectation of no association (genomic control infl ation factor λ 1000 =1·009; appendix p 74). In the main analysis (all cases of osteoarthritis vs population-based controls), 28 SNPs (representing 12 independent signals) had a p value of less than 1·0×10 -⁵ compared with fi ve SNPs according to the null expectation (binomial test p=5·0×10 -¹³; appendix p 12, p 36). We checked for false positives that were attributable to population stratifi cation by adjusting our analyses with the fi rst ten ancestry-informative principal components: our results did not change qualitatively (appendix p 6, p 75). New signals were not detected with HapMap-based imputation across the genome (appendix p 3, p 6, pp 60-61).
After large-scale replication, 71 (55%) of 129 signals taken forward had eff ects in the same direction as the discovery analysis on the basis of which they had been prioritised (appendix pp 76-81). All 26 SNPs selected for further follow-up had eff ects in the same direction (binomial p=2·98×10 -⁸). Five of 26 loci had genome-wide signifi cance (p=5·0×10 -⁸) and three were very close to this (table 2) . Eff ect size estimates for seven of eight loci were lower in the replication analysis than in the discovery analysis (table 2) , with the exception of one signal (ASTN2).
The most signifi cant signal was on chromosome 3 and was followed up by two SNPs in perfect linkage disequilibrium (LD) with each other: rs11177 (allele A; fi gure A), a missense polymorphism within exon three of GNL3, coding for nucleostemin, and rs6976 (allele T; table 2), situated in the 3ʹ untranslated region (UTR) of the GLT8D1 gene. It was the only genome-wide signifi cant signal in the discovery GWAS before replication (table 2; appendix p 99) for all osteoarthritis and TJR strata (with stronger evidence for association in the TJR strata). 
Chromosome
Position
The details of the individual discovery and replication results of analyses of all cases of osteoarthritis are shown in the appendix p 99. TJR=total joint replacement. THR=total hip replacement. TKR=total knee replacement. arcOGEN=Arthritis Research UK Osteoarthritis Genetics. *Represent the same signal, r²=1; both were prioritised and showed similar p values and eff ect sizes before and after replication. †Analyses in which a subset of samples with osteoarthritis at the hip and knee are also included in the arcOGEN discovery set and in the UK replication set. ‡This signal was attenuated after adjustment for body-mass index, suggesting that the FTO locus exerts its eff ect on osteoarthritis through obesity. Three additional signals lacked genome-wide significance and therefore need to be interpreted with caution. Rs12107036 was associated with osteoarthritis in women with total knee replacement (TKR; allele G) and is located within intron 12 of TP63 (appendix p 70; table 2). Association with rs8044769 was strongest in the female osteoarthritis stratum (allele C), within intron 1 of FTO (appendix p 71; table 2). The fi nal signal was seen in the male osteoarthritis stratum at rs10948172 (allele G), situated in the vicinity of the SUPT3H gene (appendix p 72; table 2).
We investigated the eff ect of the defi nition of disease phenotype on the strength of association of the replicating signals (table 2) by comparing the results of analyses of TJR-only cases (severe endpoint of disease) and all cases (TJR and radiography combined) for the stratum that had the lowest meta-analysis p value. We noted that, after large-scale replication, four signals (rs6976, rs4836732, rs835487, and rs12107036) were stronger in the TJR meta-analysis, one signal (rs9350591) was stronger in the meta-analysis of TJR and radiographic cases, and three signals (rs10492367, rs8044769, and rs10948172) were little changed (appendix p 100).
In the discovery set analyses of two types of controlspopulation-based controls unselected for osteoarthritis (n=11 009) and osteoarthritis-free controls (n=1828)-we compared the strength of association of the three previously established osteoarthritis loci (appendix p 7, p 101) and the eight replicating signals (table 2). We noted that one signal (GDF5) was stronger in the analysis of osteoarthritis-free controls, whereas the other ten were stronger or similar in the analyses of population-based controls (appendix p 7, p 101, p 103). In the meta-analysis of discovery and replication sets, eff ect size estimates for the replicating loci were the same or smaller for all variants except one (CHST11) when we used disease-free controls, and all signals were statistically stronger in the analyses of population-based controls (appendix p 7, p 104).
Because obesity is an established risk factor for osteoarthritis, we investigated whether any of the 129 prioritised signals were attenuated after adjustment for body-mass index (BMI) with arcOGEN cases and disease-free TwinsUK control data (BMI data were not available for the population-based controls). Two SNPs (rs11107957 and rs2626053) showed greater than 100-times increase in their p value (ie, became less signifi cant) after adjustment for BMI (appendix p 5, p 105). Rs804476 in FTO was the only replicating signal to be attenuated after BMI adjustment in the discovery GWAS, but we cannot exclude the possibility that BMI adjustment might have had an eff ect on the other variants in the replication cohorts. However, in the discovery scan, the association p value at the four remaining loci that had genome-wide signifi cance and the three signals just below this threshold were not aff ected by more than one order of magnitude after adjustment for BMI.
All the studied genes were expressed within osteoarthritic or control fracture neck-of-femur joint tissues (appendix p 6, p 108).
Immunohistochemical staining showed strong nucleolar expression of nucleostemin in cytospins of primary cultured chondrocytes from human articular cartilage derived from patients with osteoarthritis (appendix p 69), and a similar pattern of staining was seen in chondrocytes from frozen sections of osteoarthritic cartilage (appendix p 69). We measured levels of nucleostemin protein expression in cultured articular chondrocytes from fi ve controls and fi ve patients with osteoarthritis. Nucleostemin was barely detectable in cultured chondrocytes from controls but was clearly detectable in cultured chondrocytes from patients with osteoarthritis (appendix p 69). When nucleostemin expression was corrected for expression of the housekeeping gene β-actin, the upregulation of nucleostemin protein levels in osteoarthritis chondrocytes versus control chondrocytes was signifi cant (p=0·003; appendix p 69).
Discussion
We have identifi ed eight novel loci that are associated with the risk of developing osteoarthritis, fi ve of which surpassed genome-wide signifi cance and three that were just less than the threshold (panel). With the addition of previously established associations on chromosome 7q22, and in the GDF5 and MCF2L genes, 6,7,9,11 the current total of osteoarthritis susceptibility loci in European populations is 11.
Our most signifi cant fi nding was in a gene-rich region of chromosome 3p21·1. Rs6976 lies within the 3ʹ UTR of GLT8D1 (glycosyltransferase 8 domain containing 1; fi gure A). Alterations in the expression of GLT8D1 could aff ect the glycosylation of cartilage proteins. Rs11177, in perfect LD with rs6976, encodes a missense variant (Arg→Gln) in the third exon of GNL3 (guanine nucleotide binding protein-like 3, or nucleostemin; fi gure A). GNL3 is expressed in mesenchymal stem cells, from which chondrocytes are derived, and regulates the G1-S phase transition in stem cells. [13] [14] [15] The function of GNL3 in bone and cartilage is not known because mice homozygous for deletion of GNL3 die on embryonic day 4. 16 However, of interest is that nucleostemin protein levels were substantially increased in cultured chondro cytes from patients with osteoarthritis compared with controls, raising the possibility that this gene might be functionally important in the pathogenesis of osteoarthritis.
Rs4836732 lies within the ASTN2 gene (astrotactin 2; fi gure B), which is highly expressed in the developing and adult brain. ASTN2 is a membrane protein that regulates surface levels of ASTN1 during neuronal migration.
17
Rs9350591 lies between the FILIP1 (fi lamin A interacting protein 1) and SENP6 (sentrin specifi c peptidase 6) genes (fi gure C). COL12A1 (collagen, type XII, alpha 1), the product of which is found in articular cartilage, 18 lies at a distance of about 326 kb. Rs10492367 is located between the KLHDC5 (Kelch domain containing 5) and PTHLH (parathyroid hormone-like hormone) genes (fi gure D). Parathyroid hormone-related protein (PTHrP) regulates endochondral bone develop ment. Results from studies of Pthrp-/-mice showed that animals who survived gestation had accelerated diff erentiation of chondrocytes in bone. 19 Rs835487 is located in the CHST11 (carbohydrate sulfotransferase 11) gene (fi gure E), which encodes a Golgi enzyme that catalyses the transfer of sulphate groups to the 4-O position of chondroitin and dermatan sulphate, important components of cartilage proteoglycans. 20 CHST11 has a role in skeletal development, signalling pathways, and cancer progression. 21 It has substantially higher expression in osteoarthritic cartilage than in normal articular cartilage 22 and mice that are null for this gene have a disorganised growth plate, accelerated chondrocyte diff erentiation, altered patterns of signalling with transforming growth factor β and bone morphogenetic protein, and a fi brillated cartilage extracellular matrix that is characteristic of osteoarthritic cartilage. 23 Chondroitin sulfate is used as a symptomatic, slow-acting drug for osteoarthritis, recom mended by the latest Osteoarthritis Research Society International treatment guidelines, but evidence for its eff ectiveness remains controversial.
24
Rs12107036 lies within intron 12 of the TP63 gene (encoding tumour protein p63; appendix p 70). p63 null mice have serious defects in their limb, craniofacial, and epithelial development. 25, 26 Rs8044769 lies within FTO (appendix p 71), a well established locus that is associated with fat mass and obesity 27 and is in partial LD (r²>0·6) with the reported index BMI-associated SNPs. This signal was attenuated after adjustment for BMI, suggesting that the FTO gene exerts its eff ect on osteoarthritis through obesity. Rs10948172 occurs between CDC5L (CDC5 cell division cycle 5-like) and SUPT3H genes (suppressor of Ty3 homologue; appendix p 72). At a distance of 500 kb, but possibly containing SNPs correlated with rs10948172, is the RUNX2 (runtrelated transcription factor 2) gene, which encodes a protein that is essential for osteoblast diff erentiation 28 and skeletal morphogenesis.
29 RUNX2 was identifi ed in peripheral blood expression profi les as a possible biomarker for bone metabolism in arthritis. 30 The results of our study draw attention to three important issues with respect to design and analysis that are of relevance to GWAS investigations of complex disease: defi nition of signifi cant association in view of several correlated stratifi ed analyses; eff ect of phenotype homogeneity and misclassifi cation; and allowing for power constraints when seeking replication of previously identifi ed loci. First, we analysed several specifi c nonindependent phenotypes in addition to the main analysis of all osteoarthritis cases versus controls so as to increase power to detect signals specifi c for joint, sex, or disease severity. Compelling evidence suggests that joint-specifi c genetic factors play a part in the pathogenesis of osteoarthritis 31 and that the familial concordance for hip and knee osteoarthritis is greater in surgically defi ned than in radiographically defi ned disease. [32] [33] [34] The results of these reports, in addition to the signifi cant diff erences reported in the prevalence of osteoarthritis between skeletal sites, the sexes, and radiographic versus symptomatic disease, 35 underpin our decision to stratify our data by site of osteoarthritis (hip or knee), sex, sex with site, and the two modes of osteoarthritis defi nition (radiographic and joint replace ment) that we have used. That most of the loci we have identifi ed are associated with osteoarthritis at a par ticular joint site provides genetic
Panel: Research in context
Systematic review
We searched PubMed for articles in English with a combination of the terms "osteoarthritis" and "genetic" to identify reports of loci encoding susceptibility for osteoarthritis. We then focused on those in which genetic associations had been identifi ed with a compelling level of signifi cance (p≤5×10 ⁸) and with replication. This gave three loci: GDF5, 7q22, and MCF2L. These formed the basis by which we put our GWAS results into context. In our search we also took advantage of the extensive knowledge of several of the arcOGEN investigators who have published many reviews about the genetics of osteoarthritis.
Interpretation
We identifi ed eight novel genetic risk loci for osteoarthritis. Two are close to functional candidate genes that suggest clinical implications for osteoarthritis. CHST11 codes for an enzyme that modulates cartilage proteoglycan, with proteoglycan modulation being an active area of osteoarthritis therapeutic development; nutraceutical compounds, such as chondroitin sulfate, have been extensively studied. Although the evidence of effi cacy of such compounds in relieving signs and symptoms of osteoarthritis is weak, our results suggest that alternate therapeutic approaches acting on this same pathway could be clinically benefi cial. Novel anabolic treatments for osteoporosis have been developed with peptide fragments based on parathyroid hormone, and our results suggest that investigating these compounds in the treatment of osteoarthritis, or assessing endpoints of osteoarthritis in previous clinical trials of parathyroid hormone, would now be sensible. Furthermore, the association with FTO draws attention to the interplay between bodyweight and osteoarthritis, and emphasises existing clinical advice that loss of excess bodyweight is a clinical recommendation for symptom relief and avoidance of osteoarthritis. Our demonstration that osteoarthritis risk loci are on the whole specifi c to either the hip or the knee informs the clinician that the pathophysiological process of this chronic disease is likely to have joint-specifi c components that need to be borne in mind when developing treatment regimens.
evidence that the aetiopathogenesis of osteoarthritis is not uniform, but that joint-specifi c risk factors are in operation. A conservative Bonferroni correction, assum ing the inde pendence of these highly correlated specifi c phenotypes, would artifi cially move the p-value threshold of declaring genome-wide signifi cant association to 2·08×10 -⁹. 36 In this work, we draw attention to eight novel associations with osteoarthritis based on a combination of statistical evidence of association, corroborative evidence from large-scale replication, and biological insights aff orded by the replicating loci that we noted (eg, PTHLH and CHST11, both excellent biological candi dates, would not have surpassed the more stringent threshold).
Second, we accrue evidence that, in general, analyses of patients ascertained by the more stringent criterion of arthroplasty have power advantages over those including radiographically diagnosed cases, emphasising the value of patient phenotype homogeneity (appendix p 100). All eight loci reported in this study were prioritised on the basis of analyses of osteoarthritis-status-agnostic controls, indicating that the large increase in sample size aff orded by the use of population-based controls might have power advantages despite potential misclassifi cation (appendix pp 101-04).
Third, we assessed evidence for association at the three previously reported osteoarthritis loci in our discovery GWAS. We detected signals with p=0·002 to p=6×10 -⁴ for the chromosome 7 and MCF2L loci, but little evidence for association at GDF5. These results are in keeping with fi ndings in other complex disease discovery GWAS 37 and can be ascribed to a combination of power, stochastic variation in allele frequency estimates, and the absence of the index variant from the genotyping platform (appendix p 7, p 101).
We have studied common variants and therefore the fi ndings of our report cannot be used to estimate the eff ect that rarer variants might have on causing osteoarthritis. Further, although our discovery sample size of 7410 cases is the largest yet used for osteoarthritis, the sample was stratifi ed; an analysis of larger stratifi ed subsets might show additional associated loci. In our study, we focused on Europeans and it will be of great interest to assess whether these loci have global relevance to osteoarthritis risk through similar studies of nonEuropean cohorts with osteoarthritis.
All eight identifi ed loci are represented by common SNPs (minor allelic frequency 0·11-0·50) and have small eff ect sizes (allelic ORs from 1·11 to 1·21). In keeping with other common complex trait studies, these fi ndings indicate that common SNPs with large eff ect sizes are not likely to have a role in the pathogenesis of osteoarthritis. Association at the index SNPs reported here does not imply causality. Functional studies will be necessary to pinpoint the precise func tional variants. The eight signals identifi ed in this study have a combined sibling recurrence risk (λs) estimate of 1·028 and account for only a small fraction of familial clustering of osteoarthritis. This outcome leads us to advocate larger-scale sample sizes, typically achieved through GWAS meta-analysis eff orts in complex traits. The arcOGEN GWAS is the largest study of osteoarthritis genetics so far and has suffi cient power to detect slight eff ects at common loci at the genomewide signifi cance level (eg, 80% power to detect an allele with frequency 0·35 and allelic OR of 1·15). We have established novel loci represented by common SNPs that confer a slight risk for osteoarthritis and are associated with the clinically important phenotype of TJR. These results provide a basis for functional studies to identify the underlying causative variants, biological networks, and molecular cause of osteoarthritis.
